Deadline extended to Friday, August 12th, 2016
Click here to download the abstract form
Words of Welcome
On behalf of the organizing committee we are pleased to welcome you to the Canadian Conference on Myelodysplastic Syndromes taking place Sept 9 & 10th, 2016, in Quebec City. We are very excited to have with us a stellar group of international experts in MDS reviewing the new developments in this rapidly evolving field.
The scope of this meeting will highlight both recent research findings elucidating the pathophysiology of the disease, as well as changes in classification and therapeutic advances that have had a large impact in the management of MDS patients. We look forward to an even greater availability of therapeutic options for MDS patients as advances in understanding the biology of MDS are translated into the clinic.
Case presentations will highlight current treatment standards and feature discussions of where the new therapies could be positioned. There will be opportunity for audience participation via keypad polling devices with members of the clinical faculty featured during the panel discussion. We aim to bring a Canadian perspective to the management of MDS patients and look forward to your input as to ways in which we can work together to optimize the care of our patients.
The lunch period of both conference days will offer the opportunity for informal "meet the expert" sessions at the dining tables.
In addition, a mini-conference dedicated to oncology nurses and pharmacists is planned for the morning of September 10th. Speakers from the nursing, pharmacy, and medical disciplines will be presenting. There will be two simultaneous programs, one in French and one in English.
We look forward to seeing you in the historic city of Quebec!
On behalf of the Planning Committee,
Dr. Robert Delage, Chair CCMDS, Quebec City, Quebec
Dr. Rena Buckstein, Toronto, Ontario
Dr. Brian Leber, Hamilton, Ontario
This meeting has been designed to meet the educational needs of hematologists, internists, researchers, general practitioners in oncology, practitioners in laboratory medicine, residents, fellows, nurses, pharmacists and other health care providers involved in the management of patients with MDS.